SZLSF (StageZero Life Sciences) Accounts Payable: $3.99 Mil (As of Sep. 2024)

What is StageZero Life Sciences Accounts Payable?

StageZero Life Sciences SZLSF 10 Accounts Payable is $3.99 Mil as of Sep. 2024. GuruFocus rates SZLSF with a GF Score™ of 10/100.

StageZero Life Sciences's Accounts Payable for the quarter that ended in Sep. 2024 was $3.99 Mil.

StageZero Life Sciences's quarterly Accounts Payable declined from Mar. 2024 ($3.93 Mil) to Jun. 2024 ($3.88 Mil) but then increased from Jun. 2024 ($3.88 Mil) to Sep. 2024 ($3.99 Mil).

StageZero Life Sciences's annual Accounts Payable declined from Dec. 2020 ($1.25 Mil) to Dec. 2021 ($0.74 Mil) but then increased from Dec. 2021 ($0.74 Mil) to Dec. 2022 ($2.82 Mil).

StageZero Life Sciences Accounts Payable Related Terms

StageZero Life Sciences Accounts Payable Historical Data

* Premium members only.

The historical data trend for StageZero Life Sciences's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

StageZero Life Sciences Accounts Payable Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable

Get a 7-Day Free Trial

2.04

1.35

1.25

0.74

2.82

StageZero Life Sciences Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24	Jun24	Sep24
Accounts Payable	Get a 7-Day Free Trial															3.52	3.67	3.93	3.88	3.99

10GF Score

StageZero Life Sciences Ltd SZLSF

Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

StageZero Life Sciences Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →

What does a Accounts Payable of $3.99 Mil mean?

StageZero Life Sciences (SZLSF) has a Accounts Payable of $3.99 Mil as of Sep. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on StageZero Life Sciences and its competitors.

Is StageZero Life Sciences' Accounts Payable too high?

StageZero Life Sciences' current Accounts Payable is $3.99 Mil. Overall, StageZero Life Sciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.

How does StageZero Life Sciences' Accounts Payable compare to IDTA and TTOO?

StageZero Life Sciences' Accounts Payable of $3.99 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Accounts Payable for a Medical Diagnostics & Research company?

A good Accounts Payable depends on the Medical Diagnostics & Research industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Accounts Payable mean?

A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on StageZero Life Sciences and its competitors. StageZero Life Sciences's current Accounts Payable is $3.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is StageZero Life Sciences stock overvalued right now?

StageZero Life Sciences (SZLSF) has a current Accounts Payable of $3.99 Mil. The current Accounts Payable is $3.99 Mil. StageZero Life Sciences' overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Accounts Payable calculated?

Accounts Payable is calculated from a company's financial statements. For StageZero Life Sciences (SZLSF), the current Accounts Payable is $3.99 Mil as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

StageZero Life Sciences Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies IDTA TTOO NSTM TMO DHR IDXX XSWX:LONN SHSE:603259 A IQV MTD LH NTRA DGX WAT XPAR:BIM ILMN MEDP ICLR XPAR:ERF

Address 70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

10GF Score

Get the complete analysis for SZLSF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01

Price

View SZLSF Analysis

See Accounts Payable data for all stocks →